Abstract
Objective To investigate the value of methyl thiazolyl tetrazolium assay (MTT) in predicting drug sensitivity of breast cancer cells in vitro. Methods From January 2010 to July 2016, one hundred and ninety-two patients with breast cancer who underwent modified radical mastectomy or breast conserving surgery (no preoperative radiotherapy or chemotherapy) in the Shanghai Fengxian District Central Hospital were selected.MTT method was used to determine the inhibitory level and sensitivity of 12 drugs and 3 chemotherapy regimens to primary cultured cancer cells of 192 patients with breast cancer. Results (1)The sensitivity of breast cancer cells to 12 drugs were in sequence from high to low as follows: Paclitaxel (PTX) > Epirubicin (EPI) > Cisplatin (DDP) > 5-Fluorouracil (5-FU) > Mitoxantrone (MIT) >Vincristine (VCR) > Pirarubicin (THP) > Isosophosphamide (IFO) > Carboplatin (CBP) >Cyclophosphamide (CTX) > Methotrexate (MTX) > Changchun Rui bin (NVB). The sensitivity of chemotherapy regimens in the three groups from high to low was docetaxel/doxorubicin/cyclophosphamide (TAC)>cyclophosphamide/epirubicin/fluorouracil (CEF)>cyclophosphamide/methotrexate/fluorouracil (CMF). The sensitivity rates of PTX, EPI and DDP were 54% (104/192), 42% (81/192) and 37% (71/192) respectively.(2) The average inhibitory rates of DDP, CBP and MIT in stage III breast cancer was higher than those in stage I and II breast cancer, and the differences were statistically significant (F=11.14, 4.303, 3.182, P<0.05). (3) HR-breast cancer is more sensitive than HR+ breast cancer, PTX, EPI, THP, MIT in HER-2(+ ) breast cancer is more sensitive than in HER-2(-)breast cancer. Conclusion As a widely used drug sensitivity test method, MTT assay has a certain reference value for screening sensitive drugs and selecting clinical chemotherapy regimens in neoadjuvant chemotherapy of breast cancer.PTX, EPI and DDP are more sensitive to other breast cancer cells than other drugs.Chemotherapy based on in vitro susceptibility results improves the efficiency of chemotherapy and decreases the proportion of changes in chemotherapy schemes due to inefficiency. Key words: MTT assay; Breast cancer; Cell; Chemosensitivity test
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
